Lataa...
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
Around 4% of advanced non-small-cell lung cancers (NSCLCs) have an ALK rearrangement at the time of diagnosis. This molecular feature is more frequent in young patients, with no/light smoking habit and with adenocarcinoma pathological subtype. Crizotinib is a tyrosine kinase inhibitor, targeting ALK...
Tallennettuna:
| Julkaisussa: | Lung Cancer (Auckl) |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5310701/ https://ncbi.nlm.nih.gov/pubmed/28210164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S99303 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|